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Latent transcription of the latency-associated nuclear antigen (LANA/ORF73) of Kaposi's sarcoma-associated herpesvirus is driven by the
LANAp-c. Complexity arises during lytic reactivation, however, as the bicistronic K14/vGPCR transcript initiates 32 bp downstream of LANAp-c
in the opposite orientation. We identify an Rta/ORF50-inducible LANA promoter (LANAp-i) that is distinct from the LANAp-c. LANAp-c is
unaffected by Rta/ORF50. Utilization of the second, downstream LANAp-i explains how LANA and K14/vGPCR are simultaneously transcribed
during de novo infection or lytic reactivation. Transactivation of LANAp-i and K14/vGPCRp requires the C-terminal activation domain of Rta/
ORF50 and is mediated by DNA-binding-dependent and -independent Rta/ORF50 mechanisms. Transcriptional profiling following viral
reactivation support promoter reporter phenotypes. In sum, cis-elements within the LANAp were selected to ensure faithful expression of LANA
and other genes regulated by LANAp during all stages of the KSHV lifecycle despite potential interference from K14/vGPCRp activity.
© 2006 Elsevier Inc. All rights reserved.Keywords: KSHV; LANA; K14; vGPCR; Rta; ORF50; TranscriptionIntroduction
All Herpesviridae display a tightly regulated program of
gene expression (reviewed in Roizman (1996)). KSHV is no
exception and can enter one of two modes of infection: (a) latent
infection in which the viral genome persists in the host cell with
restricted viral gene expression and without cell destruction and
(b) lytic infection in which all viral genes are expressed,
infectious progeny are generated, and the host cell is destroyed.
During latency, all KSHV-infected cells express the viral
latency-associated nuclear antigen (LANA/ORF73) (Dittmer et
al., 1998; Dupin et al., 1999). LANA is the predominant target
of anti-KSHV antibodies in infected individuals. It is necessary
and sufficient for latent viral episome persistence (Ballestas et
al., 1999; Cotter and Robertson, 1999; Hu et al., 2002; Ye et al.,
2004). Although LANA shows no homology at the DNA
sequence level, its function and structural features are
reminiscent of the Epstein Barr virus EBNA-1 and EBNA-2⁎ Corresponding author. Fax: +1 919 962 8103.
E-mail address: ddittmer@med.unc.edu (D.P. Dittmer).
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doi:10.1016/j.virol.2006.03.006proteins. LANA contains a central region of acidic repeats
(EEDD, DE(E/Q)QQ, and LEEQEQEL between amino acids
(aa) 338–840) a leucine zipper (LEEQEQEL at aa 840), a
nuclear localization sequence and an N-terminal proline-rich
region. The C-terminus of LANA binds to a 17-bp motif
(LANA binding sites 1 and 2, LBS1 and LBS2) in the KSHV
terminal repeats (TR) with a binding constant of 1.5nM. This
motif is duplicated and repeated in the context of the TR. It is
necessary and sufficient for latent episome replication (Garber
et al., 2002, 2001). While LANA binds the KSHV genome
through its C-terminus, LANA also binds to cellular chromatin
and mitotic chromosomes. Binding to cellular chromatin and
chromosomes is mediated through multiple mechanisms,
primarily by LANA's N-terminus. In this manner, the LANA
protein tethers the KSHV episome to cellular chromatin and
chromosomes thereby ensuring proper segregation during host
cell division (Ballestas et al., 1999; Cotter and Robertson, 1999;
Kedes et al., 1997; Kellam et al., 1997; Moore and Chang,
1998; Rainbow et al., 1997; Szekely et al., 1999). Experimental
abrogation of LANA expression through siRNA or genomic
knockout leads to loss of KSHVepisomes from latently infected
cells (Godfrey et al., 2005; Ye et al., 2004).
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(LANAp) (Dittmer et al., 1998; Sarid et al., 1999; Talbot et al.,
1999). Through alternative splicing, the LANA promoter also
regulates expression of the viral cyclin D homolog (vCYC/
ORF72) and a viral FLICE inhibitory protein (vFLIP/ORF71).
With the exception of LANA-2/vIRF-3 in primary effusion
lymphoma (PEL), all KSHV latency transcripts cluster to one
major locus that includes LANA, vCYC, vFLIP, and Kaposin/
K12 (Dittmer et al., 1998; Li et al., 2002; Sadler et al., 1999;
Sarid et al., 1999; Talbot et al., 1999). This locus also
encompasses the KSHV miRNAs (Cai et al., 2005; Pfeffer et
al., 2005; Samols et al., 2005). Spatial clustering underscores
the importance of this region and sets the latency-associated
locus apart from all other viral transcription units. It is possible
that during latency, all genes within the latency-associated locus
can be derived by alternative splicing of nascent RNAs under
control of the LANAp. Transcriptional profiling showed that
during viral latency in PEL and in primary KS biopsies, LANA,
vCYC, vFLIP, and Kaposin were constitutively expressed
(Dittmer, 2003; Fakhari and Dittmer, 2002; Jenner et al., 2001;
Paulose-Murphy et al., 2001). Under conditions where other
KSHV promoters were silenced, the LANA promoter remained
constitutively active. CpG islands within the LANAp are
constitutively unmethylated in both PEL and KS (Chen et al.,
2001) and are associated with an “open” chromatin environ-
ment. This is in contrast to the promoter for the viral immediate
early protein Rta/ORF50. Treatment with sodium butyrate, an
inhibitor of histone deacetylases (HDACs), did not change the
acetylation status of histones H3 and H4 on the LANAp since
the promoter was already de-repressed, contrasting the response
observed on the Rta/ORF50 promoter and other regions of the
viral genome (Lu et al., 2003). We previously reported a
LANAp-luciferase reporter that showed constitutive activity in
all cell lines tested including KSHV-positive BCBL-1 B-cells,
KSHV-negative BJAB B-cells, HEK293 epithelial cells, and
SLK endothelial cells (Jeong et al., 2001, 2004). Moreover, a
1861-bp DNA fragment originating at the LANA AUG at
position 127,300 and extending to position 129,161 (−1299 bp
relative to the latent transcription start site) was able to direct
B-cell-specific reporter gene expression in transgenic mice
(Jeong et al., 2002). This demonstrated that host cell transcrip-
tion factors in the absence of any viral transactivators suffice to
direct LANAp activity and, by inference, LANA, vCYC, vFLIP,
Kaposin, and miRNA transcription during viral latency.
The LANAp is positively regulated by LANA itself through
a consensus DNA-binding element within the minimal LANAp
that is similar to the LBS1 within the KSHV TRs (Jeong et al.,
2004). This establishes a self-stabilizing feedback loop to
maintain KSHV latency (Wong et al., 2004; Renne et al., 2001;
Chiou et al., 2002). In addition to specific DNA binding, LANA
can act as a promiscuous transcription factor independent of its
own DNA-binding recognition element through interaction with
cellular proteins including: Sp-1 (Verma et al., 2004), RBP-jκ
(also known as CSL) (Lan et al., 2005a), p53 (Friborg et al.,
1999), Rb (Radkov et al., 2000), GSK-3β (Fujimuro et al.,
2003), CBP (Lim et al., 2001), ATF4/CREB2 (Lim et al., 2000),
as well as the chromatin modifying factors SAP30, mSin3A andCIR (Krithivas et al., 2000), meCP2, DEK (Krithivas et al.,
2002), and Histone H1 (Cotter and Robertson, 1999).
Deletion analyses mapped the minimal core promoter region
of the LANAp from −88 to +10 (nt 127,968–127,870) (Jeong et
al., 2004) relative to the latent transcription start site at 127,880
(Dittmer et al., 1998). However, the presence of additional cis-
elements flanking the core promoter significantly contributed to
LANAp activity. Distal sequences from −88 up to −279
(nt 127,968–128,159) as well as sequences within the 5′-UTR
from +10 down to +271 (nt 127,870–127,609) enhanced
reporter activity more than 10-fold relative to the minimal core
promoter (Jeong et al., 2004). Here, we explore the impact of
these regions to LANAp activity during latency and in the
presence of the KSHV lytic-switch protein Rta/ORF50. This
report demonstrates the presence of a second, ORF-proximal
LANAp (here termed the LANAp-i), which was first posited by
Hayward and colleagues on the basis of sequence analysis
(Nicholas et al., 1998) and more recently investigated by
Matsumura et al. (2005). This new promoter was inactive
during viral latency but, as opposed to the constitutive LANAp,
was responsive to Rta/ORF50. Promoter switching between the
constitutive LANAp and the novel LANAp-i provides a model
how an overlapping lytic promoter region can act bidirection-
ally to initiate transcription of both the LANAp-i and the K14/
vGPCR promoter (K14p), which directs transcription on the
opposite strand in the opposite orientation. Here, we indepen-
dently report and confirm the presence of the Rta/ORF50-
inducible LANA promoter. We further show that the C-terminal
domain of Rta/ORF50 is necessary for transactivation of the
LANAp, and that an established Rta/ORF50 mutant with
increased DNA-binding activity also enhanced activation of
LANAp-i and K14p compared to wild-type Rta/ORF50. Yet, an
Rta/ORF50 mutant that fails to bind DNA could still somewhat
transactivate these promoters suggesting additional modes of
regulation by Rta/ORF50 perhaps through cellular transcription
factors, such as RBP-jκ.
Results
Basal LANA promoter activity
While the minimal core promoter region is defined from −88
to +10 bp, the inclusion of additional upstream or downstream
sequences greatly increased reporter activity (Jeong et al., 2001,
2004). Of all prior deletion reporters of the LANAp, the +271/
−279 luciferase reporter (pDD83, encompassing nucleotides
127,607–128,159) consistently gave the highest basal activity
in all cell lines tested. Hence, we chose the reporter plasmid
−279/+271 for further analysis. We have used plasmid
nomenclature that describes the LANAp sequence that is
present in the particular plasmid relative to the major latent
LANA transcription start site at nt 127,880. Deletion mutants
were derived by first generating novel NcoI, NheI or SacI sites
through targeted mutagenesis and then collapsing the reporter
by restriction digest and subsequent re-ligation. LANAp
deletion reporters that failed to yield significant activity were
subcloned into empty reporter vector (pGL3basic) to exclude
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frame that may have unintentionally resulted from PCR. Fig. 1
shows a diagram of the parental LANAp plasmid +271/−279
and six downstream deletion mutants (panel A) and their
constitutive reporter activity in HEK 293 cells (panel B).
Deletion of +271 to +47 did not affect constitutive LANAp
activity. However, deletion of 12 more bp up to +35 reduced
LANAp activity to 20% that of the parental reporter +271/−279,
a level that was still approximately 20-fold greater than
background levels of the pGL3basic control. Further deletion
of the LANA 5′-UTR up to and including the transcriptional
start site at 127,880 completely abolished LANAp constitutive
activity, as expected (mutant −1/−279). To verify these
observations in an alternative cell line, we repeated these
experiments in KS-tumor derived SLK cells. SLK cells are
KSHV negative, of endothelial cell origin (CD34pos, Ulex
Lectinpos) and form vessel-like structures in Matrigel (Herndier
et al., 1994; Lunardi-Iskandar et al., 1995). These cells can be
infected with KSHV and rapidly enter latency (Grundhoff and
Ganem, 2004). By comparison to epithelial-derived, highly
passaged HEK293 or HeLa cells, the rate of spurious
transcription is much lower in SLK cells leading to minimal
background reporter activity. The six 3′-LANAp deletion
reporters produced a similar trend of constitutive promoter
activity in SLK cells (Fig. 1C) compared to HEK293 cells (Fig
1B) with the exception of mutant +205/−279. Mutant +205/
−279 displayed promoter activity comparable to parental
reporter in HEK293 cells (Fig. 1B) but only approximately
23% activity compared to parental reporter in SLK cells, which
still was greater than 100-fold of empty vector (Fig. 1C). In both
cell lines, mutants +186/−279 and +141/−279 display lower
promoter activity compared to parental reporter +271/−279.
Further deletion with mutant +47/−279 resulted in a restoration
of maximal promoter activity comparable to parental reporter
+271/−279 in both cell lines. The reasons for these effects areFig. 1. Deletion analysis reveals that the constitutive 127,880 start site is required. (A
−1. Indicated are the latent start-site (arrow, LANAp-c), Rta/ORF50-inducible start
element (asterisk), DPE (circle, D), Sp1 site (S, diamond), and LANAp-c TATA ele
HEK293 cells. HEK293 cells were transfected with the indicated plasmids. Data
experiments normalized by co-transfected β-galactosidase activity. SD, standard dev
deletion mutants in SLK cells. SLK cells were transfected with the indicated plasmicurrently unknown; however, these data implicate an active role
for the 5′-UTR in regulation of latent LANAp activity.
The LANAp is active if regions −88 bp upstream of the
127,880 start site are present and inactive if only −57 bp
upstream are present (Jeong et al., 2001). To further define the
upstream region necessary for constitutive LANAp activity, a
second series of LANAp deletion mutants with sequential
deletion of upstream promoter region were assayed for basal
activity. Fig. 2 shows a diagram of these upstream LANAp
deletion mutants (panel A) and their reporter activity in
HEK293 cells (panel B) and in SLK cells (panel C). We
observed an increase in promoter activity of mutants +271/−238
and +271/−233 compared to the parental reporter +271/−279 in
HEK293 cells (Fig. 2B). More important and consistent is the
loss of≥70% reporter activity if −160 bp or fewer are included.
This defines −160 to −273 as an ancillary promoter regulatory
region. Over 90% of reporter activity was lost if the TATA box
was deleted (−50). The exception to this trend was a single
deletion mutant +271/−93, which retained wild-type activity
even though the adjacent deletion constructs (both 5′ and 3′)
lost activity. Mutants +271/−65 and +271/−61 showed minimal
promoter activity in both cells lines and further deletion from
−50 all the way to +58 resulted in inactive promoters, thus
further defining the 5′-boundary of the core LANAp and
demonstrating that no other constitutive promoters are present
within the +58 to +271 region.
LANA promoter response to Rta/ORF50
Having generated a panel of LANAp deletion mutants, some
of which contain lytic K14/vGPCR promoter (K14p) elements,
we investigated the effect of Rta/ORF50 co-expression on
reporter activity in the context of a functional LANAp. The full-
length LANAp consistently showed increased activity in the
presence of Rta/ORF50 in 293 cells (Fig. 3B) and in SLK cells) Schematic of LANAp reporters with sequential deletions spanning +205 up to
site at 127,610–11 (arrow, LANAp-i), RBP-jκ site (black oval), putative TATA
ment (box). (B) Promoter activity of LANAp downstream deletion mutants in
represent the mean relative luciferase activity (RLU) after 48 h of triplicate
iation is indicated by error bars. (C) Promoter activity of LANAp downstream
ds. Data are represented as in panel B.
Fig. 2. The core LANAp is the only constitutive promoter within nt 127,607–128,159. (A) Schematic of LANAp reporters with sequential deletions spanning −279
down to +58. Indicated are the latent start-site (arrow), putative TATA elements (asterisk), RBP-jκ site (black oval), DPE (circle, D), Sp1 site (S, diamond), LANAp-c
TATA element (box). (B) Promoter activity of in HEK293. Cells were transfected with the indicated plasmids. Data represent the mean relative luciferase activity
(RLU) after 48 h of triplicate experiments normalized by co-transfected β-galactosidase activity. SD, standard deviation is indicated by error bars. (C) Promoter
activity of in SLK cells. Cells were transfected with the indicated plasmids. Data represent the mean relative luciferase activity (RLU) after 48 h of triplicate
experiments normalized by co-transfected β-galactosidase activity. SD, standard deviation is indicated by error bars.
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by comparison to bona-fide KSHV lytic promoters (this work
and Damania et al., 2004). We first assayed our panel of
downstream deletion mutants for Rta responsiveness in 293
cells and found that deletion of nt +271 to +205 decreased Rta/
ORF50 responsiveness by 70–100%, demonstrating that this
region (nt 127607–127675) was required for Rta responsive-Fig. 3. Rta/ORF50 responsiveness of the LANAp requires nt 127,607–127,675. (A
127,880 (arrow, LANAp-c) and lytic start site at 127,610–11 (arrow, LANAp-i), put
Sp1 site (S, diamond), and LANAp-c TATA element (T, box). (B and C) Promoter
HEK293 cells (panel B) or SLK cells (panel C) were transfected with the indicated r
activities were normalized to basal activity of parental +271/−279 LANAp activity;ness in 293 cells (Fig. 3B). In SLK cells, a similar trend was
observed whereby deletion of the same region (nt +271 to +205)
reduced Rta/ORF50 responsiveness by 70% (Fig. 3C);
however, the overall response to Rta/ORF50 in SLK cells was
greater than in 293 cells, therefore, despite a 70% decrease in
activation by Rta/ORF50, a significant activation was still
observed compared to basal activity of the +205/−279 reporter.) Schematic of LANAp used in this study. Indicated are the latent start-site at
ative TATA elements (asterisks), RBP-jκ site (black oval), DPE (D, white oval),
activity in the presence (hashed bars) or absence (black bars) of Rta/ORF50.
eporter plasmids in the presence of either Rta/ORF50 or empty vector. Reporter
standard error is indicated by error bars.
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to +145) decreased promoter activation by 80–100%. In both
cell lines, the core latent LANAp was not activated by Rta/
ORF50 in isolation (Figs. 3B and C, reporter +35/−279)
demonstrating the Rta/ORF50-responsive elements are located
downstream from the core latent LANA promoter.
We then assayed the upstream LANAp mutants in response
to Rta/ORF50 expression in the same two cells lines (Figs. 4A
and B); the relative position of these mutants is summarized in
Fig. 4C. While mutants with less than −61 bp showed no
constitutive promoter activity (Figs. 4A and B, mutants +271/
−50 to +271/+58 black bars), upon expression of Rta/ORF50
the same reporters became active in both 293 and SLK cells
(Figs. 4A and B, hashed bars). Indeed, five mutants that did not
contain the minimal core LANAp (mutants +271/+11 to +271/
+58) exhibited promoter activity in the presence of Rta/ORF50.
The fold activation in response to Rta/ORF50 expression of
these five Rta-dependent reporters was higher than for parental
reporter +271/−279 (compare range of 8- to 22-fold activationFig. 4. Rta/ORF50 responsiveness of LANAp deletion mutants confirms the novel do
cells (panel A) and in SLK cells (panel B). Cells were transfected with the indicated
ORF50; standard error is indicated by error bars. (C) Schematic of LANAp for visual
relative to the latent start site at nt 127,880.for mutants +271/+11 to +271/+58 versus 5-fold for +271/
−279, Fig. 4A, hashed bars). To distinguish between the latent
constitutively active LANA promoter (mutant +47/−279) and
the Rta/ORF50-dependent promoter region (mutant +271/+36),
we will refer to them as the LANAp-c and LANAp-i (for
constitutive and inducible), respectively.
In an effort to quantify the LANA promoter response to Rta/
ORF50, we performed a dose-response experiment. We focused
on the Rta-dependent LANAp-i or the latent LANAp-c
individually or in their natural sequential context within the
parental reporter construct +271/−279, which for simplicity
from here on will be referred to as the LANAp-FL, for full-
length (see Fig. 5A for diagram). The lytic K14 promoter
reporter served as our positive control since it is Rta/ORF50-
responsive (Chiou et al., 2002; Jeong et al., 2001; Liang and
Ganem, 2004). As expected, the K14p was dose-responsive to
increasing amounts of Rta/ORF50 protein (see Fig. 5B for
luciferase activity and 5G for Rta/orf50 protein levels). Of note,
within the K14p construct (which encompasses nt 127,297–wnstream LANA promoter, LANAp-i. (A and B) Promoter activity in HEK293
reporter plasmids in the presence (hashed bars) or absence (black bars) of Rta/
reference. Positions of representative deletions are shown below the dotted lines
Fig. 5. The LANAp-i and K14p, but not LANAp-c are dose-responsive to Rta/ORF50. (A) Schematic of promoter reporters used in this assay. Transcription start sites
are shown as arrows and indicate transcript orientation. RBP-jκ site (black oval), K14p Rta/ORF50-responsive elements (Chiou et al., 2002) (white ovals, black oval),
DPE (D, white circle), Sp1 site (S, diamond), and LANAp-c TATA element (T, box) are depicted. (B) K14/vGPCR promoter activity shown as fold activation by Rta/
ORF50 along the y-axis against increasing dose of Rta/ORF50 expression vector along the x-axis (0, 1:0.5, 1.1, 1:5 ratio of promoter reporter:expression vector);
standard error is indicated by error bars. (C) LANAp-i promoter activity shown as described in panel B. (D) LANAp-FL promoter activity shown as described in panel
B. (E) LANAp-c promoter activity shown as described in panel B; note change in y-axis scale. (F) Empty reporter (pGL3basic) background activity shown as
described in panel B; note change in y-axis scale. (G) Detection of myc-tagged Rta/ORF50 and cellular beta-actin protein levels by immunoblot from a representative
LANAp-i dose-response experiment.
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Therefore, LANAp-c is inactive, and no interfering transcripts
could be produced from the opposite strand. The K14p, LANAp-
i, and LANAp-FL exhibited increased promoter activity with
increasing amounts of Rta/ORF50 expression vector (Figs. 5B,
C, and D). In contrast, no concentration of Rta/ORF50
expression vector had any effect on LANAp-c activity (Fig.
5E, note the change in scale). These data establish the presence
of two separate promoters the LANAp-c and the LANAp-i that
each respond differently to the lytic switch protein, Rta/ORF50.
We also noticed the magnitude of Rta/ORF50-responsivepromoters was quite different. The K14p was activated by Rta/
ORF50 up to 695-fold by the same amount of Rta/ORF50 that
activated the LANAp-i 251-fold and the LANAp-FL only 43-
fold. This phenotype is consistent with the hypotheses (a) that
sequences common to the LANAp-i and K14p (nt 127607–
127845) mediate Rta/ORF50 responsiveness and (b) that the
upstream constitutive LANAp-c (nt 127845–128159) inhibits
Rta/ORF50 responsiveness of the LANAp-i in the context of the
full-length promoter, perhaps due to promoter interference.
To visualize the latent and lytic phenotypes of each LANAp
mutant, we plotted the basal constitutive promoter activity of
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ORF50. As seen in Fig. 6, all of the “upstream” LANAp
deletion reporters (circles) were responsive to Rta/ORF50 at
least 5-fold (mutants +271/−238 to +271/+58), which is
explained by the fact that each of these constructs contains
the Rta-dependent LANAp-i region. However, only those
“upstream” deletion reporters that also contained the latent
LANAp-c start site at 127,880 displayed promoter activity in
the absence of Rta/ORF50 (Fig. 6, mutants +271/−238 to +271/
−31). In contrast, none of the “downstream” deletion mutants
(squares) were activated by Rta/ORF50 though all retained
basal promoter activity in the absence of Rta/ORF50 expression
with the exception of one mutant, −1/−279, in which the latent
LANAp-c start site at 127,880 was deleted. By summarizing the
deletion mutant data in this manner, we observed the clear
separation of phenotypes of the latent LANAp-c and the lytic
LANAp-i. The overall number of different deletion mutants in
these experiments exceeds all prior studies, and our quantitative
analysis instills a high level of confidence in these observations.
We next assayed our panel of latent or lytic reporter plasmids
in response to an Rta/ORF50 expression vector in which the C-
terminal activation domain was deleted (Lukac et al., 1999). As
previously reported by Lukac et al., the C-terminal 160 amino
acids (aa 531–691) of wild-type Rta/ORF50 were deleted to
generate the ORF50ΔSTAD construct, which results inFig. 6. Constitutive LANA promoter activity is distinct from Rta/ORF50 responsiv
activation by Rta/ORF50 along the y-coordinate and by basal activity along the x-co
circles; reporters with deletions downstream of the latent start site are shown as tria
vector (pGL3basic) are shown as filled squares for reference. (Of note, the LANAp-
both basal and Rta/ORF50-induced activity are shown in blue, reporters with only Rt
Rta/ORF50 expression are shown in black.expression of a truncated Rta/ORF50 protein that is incapable
of transactivating Rta/ORF50-responsive promoters (Lukac et
al., 1999). We found that the LANAp-FL, the LANAp-i, and the
lytic K14p reporters were transactivated by wild-type Rta/
ORF50 as expected (Fig. 7, panel B hashed bars), but the
truncated Rta/ORF50 mutant ORF50ΔSTAD was unable to
transactivate any of the reporters in this assay (Fig. 7, panel B,
black bars). ORF50ΔSTAD expression did not reduce basal
constitutive activity of the LANAp-FL. These data demonstrate
that the C-terminal activation domain of Rta/ORF50 is
necessary for the transactivation of the LANAp.
Having established that the C-terminal activation domain of
Rta/ORF50 was necessary for transactivation of the LANAp-i,
we wanted to further clarify the mechanism of transactivation by
Rta/ORF50. Rta/ORF50 is known to transactivate promoters by
non-mutually exclusive mechanisms (Chang and Miller, 2004;
Chang et al., 2005; Song et al., 2003): either direct binding to
DNA sequences or by protein–protein interactions with cellular
transcription factors that mediate DNA binding. First, to test
whether direct DNA binding is involved in LANAp transactiva-
tion by Rta/ORF50, we obtained established Rta/ORF50 DNA-
binding mutants: the ORF50(KK/EE) mutant, which has in-
creased affinity for binding Rta/ORF50 response element (RRE)
DNA; the ORF50(R161A) mutant, which fails to bind RRE
DNA; and the ORF50(KK/EE;R161A) mutant, which containseness. Summary LANAp reporter activity graphed as a measure of both fold
ordinate. Reporters with deletions upstream of the latent start site are shown as
ngles. Previously characterized lytic (K14p) and latent (LANAp-FL) or empty
FL reporter contains both the LANAp-c and LANAp-i regions). Reporters with
a/ORF50-dependent activity are shown in red, and reporters that lack response to
Fig. 7. Activation of LANAp-i and K14p requires the C-terminal activation domain of Rta/ORF50. (A) Schematic of promoter reporters used in this assay.
Transcription start sites are shown as arrows and indicate transcript orientation. Putative TATA elements (asterisks), RBP-jκ site (black oval), DPE (D, white circle),
Sp1 site (S, diamond), and LANAp-c TATA element (T, box) are depicted. (B) Promoter activity of Rta/ORF50-responsive promoters depicted as relative light units
(RLU). HEK293 cells were transfected with the indicated reporter plasmids in the presence of Rta/ORF50 (hashed bars), ORF50ΔSTAD (black bars) or empty
expression vector (gray bars); SE, standard error is indicated by error bars.
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lytic LANA promoters and the K14 promoter reporter in res-
ponse to these Rta/ORF50DNA-bindingmutants. As before, the
K14p and LANAp-i reporters were activated in response to wild
type Rta/ORF50, the LANAp-c was not (Table 1). The LANAp-
FL reporter, which contains both the LANAp-i and LANAp-c
regions, displayed an intermediate phenotype compared to
LANAp-i or LANAp-c alone. This result demonstrates that in
the context of collinear orientation, the LANAp-c phenotype is
dominant over the Rta/ORF50-responsive LANAp-i.
A similar response of the LANA-c and LANAp-FL was
observed upon expression of the Rta/ORF50(KK/EE) enhanced
DNA-binding mutant. However, a comparison of the two Rta/
ORF50-dependent promoters, the LANAp-i and K14p, showed
a dramatic increase in K14p response to the KK/EE mutant,
which is not seen for the LANAp-i. This result indicates that
while the LANAp-i and K14p share overlapping promoter
elements and are both responsive the Rta/ORF50, the precise
molecular mechanism of transactivation may in fact be
different. Mutation in the conserved DNA-binding domain of
Rta/ORF50 (R161A mutant) reduced fold activation of both the
LANAp-i and K14 promoters but did not completely abolish
transactivation. This result demonstrates a requirement for an
intact DNA-binding domain of Rta/ORF50 in addition to the
requirement for its C-terminal activation domain in LANAp-i
and K14p transactivation.Table 1
Fold activation in response to Rta/ORF50 DNA-binding mutants
Reporter Fold activation
WT KK/EE R161A
LANAp-FL 10 ± 2 20 ± 4 7 ± 2
LANAp-i 126 ± 48 132 ± 8 36 ± 21
LANAp-c 2 ± 1 3 ± 1 2 ± 1
K14p 585 ± 95 2480 ± 247 147 ± 45While mutation of the DNA-binding domain of Rta/ORF50
reduced activation of the Rta/ORF50-dependent LANAp-i and
K14 promoters, it was not completely abolished which suggests
that DNA-binding was not the only mechanism at work.
Therefore we looked to cis-elements present within the
overlapping LANAp-i and K14 promoters for cellular trans-
cription factor binding sites that may contribute to Rta/ORF50
responsiveness. A consensus RBP-jκ site is located between the
K14p and LANAp-i start sites and has been previously
implicated in contributing to Rta/ORF50 responsiveness of
these promoters (Lan et al., 2005a; Liang and Ganem, 2004;
Matsumura et al., 2005) since Rta/ORF50 can bind to cellular
RBP-jκ, which results in conversion of RBP-jκ from a
transcriptional repressor to an activator.
We hypothesized that Rta/ORF50 may also modulate
LANAp transcription by utilizing RBP-jκ sites located in the
overlapping LANAp-i/K14p region at nt 127,736–127,740
(+140 to +144 with respect to the latent LANAp-c start site). To
test this hypothesis, we generated LANAp-i and K14p reporter
constructs in which this consensus RBP-jκ site was destroyed
by site-directed mutagenesis. This mutation is different from the
mutant reported by (mutant m4) Matsumura et al. (2005) in that
while they substituted the wild-type LANAp sequence at
127,736–127,740 from 5′-ACCCT-3′ to 5′-TTAAG-3′ as we
did, they in the process also created an additional deletion of nt
127,745, thus changing space relations as well as sequence. To
maximize the assay range in our experiment, we used the Rta/
ORF50(KK/EE) mutant that binds strongly to cognate DNA.
Disruption of the RBP-jκ site in the both the LANAp-i and
K14p reduced Rta/ORF50 responsiveness by 70 and 85%,
respectively, compared to wild-type promoter (Table 2). A
similar reduction (70% and 76%) in Rta/ORF50 responsiveness
was observed following expression of the isogenic Rta/ORF50
mutant that contains the R161A mutation in its DNA-binding
domain. Combining the cis RBP-jκ mutation in the LANAp-i
and K14 promoters with the DNA-binding domain mutation of
Table 2
Fold activation of Rta-dependent promoters containing either wild-type (WT) or
mutant (mut) RBP-jκ sites at nt 127736-127740 in response to Rta/ORF50
containing either wild-type or mutant (R161A) DNA-binding domain
Reporter Fold activation
KK/EE KK/EE(R161A) Residual (%)
LANAp-i WT 23 ± 3 8 ± 2 30
LANAp-i mut 6 ± 1 4 ± 1 –
Residual 30% – 20
K14p WT 406 ± 46 85 ± 1 24
K14p mut 56 ± 8 9 ± 1 –
Residual 15% – 2
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promoters to greater levels compared to mutation of either the
cis or trans element alone. This result demonstrates that in
addition to the C-terminal activation domain and the DNA-
binding domain of Rta/ORF50, the consensus RBP-jκ site
within the overlapping LANAp-i and K14p contribute to Rta/
ORF50 responsiveness.
Analysis of transcripts originating at LANAp-c or LANAp-i
following KSHV reactivation
Because the LANAp-i start site (127610–11, Matsumura et
al., 2005) is located within the first intron of the 5400 nt LANA
(LT1) and 1700 nucleotide vCYC (LT2) spliced latent mRNAs
originating at 127,880, we hypothesized that spliced latent
messages are unaffected by Rta/ORF50 acting on LANAp-i. To
test this hypothesis, we conducted array-based transcriptional
profiling of all KSHV genes in KSHV-infected BCBL-1
primary effusion lymphoma (PEL) cells at early times (12 h
post-induction) with three independent drugs known to
reactivate KSHV: ionomycin, sodium butyrate, and 12-O-
tetradecanoylphorbol-13-acetate (TPA) (Fig. 8). Therefore, onlyFig. 8. The relative abundance of KSHV transcripts originating at either the latent L
levels in KSHV-infected BCBL-1 cells at 12 h post-treatment with either 20 ng/ml TPin the context of analyzing multiple viral mRNAs simulta-
neously we discerned mRNAs that change dramatically as a
result of specific transactivation opposed to drug-induced non-
specific effects. We designed a real-time QPCR primer pair that
flanks the first LANA intron within the 5′-UTR and one that
flanks the vCYC intron, thereby only producing a product if
those introns are spliced out (Fakhari and Dittmer, 2002). The
“vCYCspl” and “LANA 5′spl” spliced mRNAs were not
significantly induced with any of the drug treatments (Fig. 8),
confirming that the LANAp-c is not affected by lytic
reactivation in the context of KSHV-infected B cells. The
mRNA for Rta/ORF50 was induced following treatment with
all three drugs, as expected. In contrast to the splice isoform-
specific primers, primer pairs located within the vCYC open
reading frame (ORF) and downstream of the LANA ORF
(“LANA” primer, nt 123,626–123,688) detected spliced and
unspliced LANA/vCYC/vFLIP mRNA, originating from
LANAp-c or LANAp-i or any RNA species that use the splice
vCYC splice acceptor at 123,776 and upstream splice donors,
including RNA species that can give rise to the KSHV miRNAs
(Cai et al., 2005; Pfeffer et al., 2005; Samols et al., 2005) by
splicing from 123,594 to 118,779. Hence, this primer pair
showed 5-fold induction comparable to LANAp-FL. This
finding is consistent with our earlier observations using
different time points that show among all the KSHV mRNAs
the latency mRNAs originating at 127,880 change the least
upon viral reactivation from PEL (Fakhari and Dittmer, 2002)
and affirms the initial classification by Sarid et al. (1998).
Discussion
The LANA protein is essential for KSHV latent persistence.
LANA and other genes, whose transcription is under control of
LANAp, are thought to contribute to malignant transformation
and survival of KS and PEL tumor cells (An et al., 2003; ChangANAp-c or lytic LANAp-i following viral reactivation. Fold increase in mRNA
A (hashed bars), 500 nM ionomycin (gray bars), or 4 mM butyrate (black bars).
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al., 2004). Hence, understanding the architecture and regulation
of the LANAp will enhance our understanding of KSHV
latency as well as yield insights into the development of
LANAp-targeted anti-tumor and/or anti-KSHV drugs. Other
than during asymptomatic latency in B cells (Dittmer et al.,
1999; Mesri et al., 1996) or in KSHV-associated tumors
(Dittmer et al., 1998; Dupin et al., 1999), LANA protein and
LANA mRNAs have been detected immediately after de novo
infection of endothelial cells and fibroblasts (Krishnan et al.,
2004) (Yoo et al., 2005). In these, KSHV rapidly establishes
latency but can be reactivated by TPA. LANA and Rta/ORF50
mRNAs were described as immediate early mRNAs. Within
24 h, Rta/ORF50 mRNA levels dropped below the level of
detection, while LANA mRNA remained constant in the now
99% latently infected culture. This prompted the search for and
eventual discovery of a novel lytic-phase LANA promoter (Lan
et al., 2005a; Matsumura et al., 2005). We have confirmed this
discovery herein.
We extend upon this observation by dissecting the
mechanism of LANAp-i activation by Rta/ORF50 and the
relation of LANAp-i to LANAp-c, as well as to the overlapping
lytic K14 promoter. The LANAp-c is constitutively active
during all forms of latency; its activity is enhanced by LANA
(Jeong et al., 2004) and independent of Rta/ORF50 (Fig. 5). In
contrast, the downstream LANAp-i is only active in the
presence of Rta/ORF50 (Figs. 3-4). The major latent transcrip-
tional start site at 127,880 and the DPE element at nt 127,850–
127,856 (+30 to +24) are required for basal LANAp-c activity.
Our sixteen “upstream” LANAp deletion mutants show that the
LANAp-c region is dispensable for LANAp-i Rta/ORF50-
dependent activity. Nucleotides 127,607–127,675 are sufficient
and required for Rta/ORF50 responsiveness and encompass the
core elements of the LANAp-i.
The LANAp-i was significantly more responsive to Rta/
ORF50 in isolation than when linked to the LANAp-c as in the
LANA-FL reporter (Figs. 3, 4 and 5). This effect could be a
result of transcript elongation ensuing from the LANAp-c
through the LANA/ORF73 5′-UTR (containing the LANAp-i),
which might prevent initiation events on LANAp-i cis regions.
Such a mechanism was previously reported for the GAL10 and
GAL7 promoters of Saccharomyces cerevisiae and for transcrip-
tion through tandem HIV-1 promoters (Greger et al., 1998;
Greger and Proudfoot, 1998). In support of this notion, deletions
of core LANAp-c regions that decreased basal promoter activity
were associated with increased Rta/ORF50 responsiveness
(Figs. 4 and 6). In contrast to our earlier finding (Jeong et al.,
2004), we found no evidence for Rta/ORF50 directly repressing
the LANAp-c at concentrations that are not globally toxic.
The LANAp-i and K14p, but not the LANAp-c, were
activated by Rta/ORF50 expression in a dose-dependent manner
(Fig. 5). The C-terminal activation domain of Rta/ORF50 was
required for transactivation of the LANAp-i and K14p. The
K14p was activated following expression of the enhanced
consensus RRE DNA-binding Rta/ORF50(KK/EE) mutant, the
LANAp-i was not. Expression of an isogenic mutant of Rta/
ORF50 that abolishes RRE-mediated DNA binding reduced butdid not completely abolish activation of the LANAp-i (Table 1).
This is the first evidence that these two promoters that share an
overlapping Rta/ORF50 responsive region may in fact be
regulated by a different molecular mechanism, and that there
may be directionality to Rta/ORF50 transactivation. Mutation of
a consensus RBP-jκ site at 127,736–127,740 reduced the ability
of Rta/ORF50 to transactivate both the LANAp-i and K14
promoters (Table 2), implicating that this site is required for the
regulation of both promoters. These data suggest a mechanism
whereby LANA transcripts derived from the LANAp-i can be
transcribed during lytic reactivation without polymerase inter-
ference by K14/vGPCR transcripts that are simultaneously
being transcribed on the complementary strand in the opposite
orientation as a result of bidirectional transactivation from the
KSHV lytic-switch protein, Rta/ORF50.
With respect to other KSHV latent transcripts, the discovery
of the LANAp-i allowed us to test an interesting prediction.
Because the LANAp-i is located within the 5′ intron of spliced
transcripts originating from the LANAp-c (i.e., downstream of
the splice donor site at nt 127,813) (Dittmer et al., 1998),
mRNAs using this splice donor should not respond to Rta/
ORF50 and should not change upon viral reactivation. This was
indeed the case (Fig. 8). Transcripts initiating from the LANAp-
i can only direct ORF73/LANA translation (as the most 5′ORF)
and ORF71/vFLIP translation through internal ribosomal
binding (Bieleski and Talbot, 2001; Grundhoff and Ganem,
2001), as well as a potential mRNA encoding LANA and
Kaposin through removal of the exon 123,594–118,779, which
contains KSHV miRNAs (Cai et al., 2005; Pfeffer et al., 2005;
Samols et al., 2005). This species would translate ORF73/
LANA as the most 5′ ORF, but not Kaposin. This observation
explains why Kaposin, which is induced and most likely
required during lytic replication, has its own Rta/ORF50
responsive promoter and ORF-proximal transcription start site
(Sadler et al., 1999). Alternatively, there may exist yet
unexplored splice donor sites downstream from the LANAp-i
that could regulate vCYC, Kaposin and the miRNAs that would
not use the proximal splice acceptor just upstream of LANA/
ORF73 at either 127,477 (Dittmer et al., 1998) or 127,314
(Sarid et al., 1999).
During de novo infection, Rta/ORF50 is present within
KSHV virions (Bechtel et al., 2005; Lan et al., 2005b) and as
such is delivered into the host cell upon infection in the absence
of LANA protein expression. Therefore, we speculate that Rta/
ORF50 protein could initially transactivate the LANAp-i and
K14/vGPCR promoters through direct DNA binding or via the
shared consensus RBP-jκ site during de novo infection. As
LANA protein expression ensues and LANA accumulates
within the cell, expression of Rta/ORF50 protein is silenced as
a result of LANA repression of the Rta/ORF50 promoter and
LANA's inhibition of Rta/ORF50′s transactivation function
(Lan et al., 2004). As a result, the LANAp-i and K14/vGPCR
promoter activity would cease and LANA-coding mRNA could
be transcribed from the latent LANAp-c, which is auto-regulated
by LANA protein. This sequence of events can establish a
positive feedback loop that is sufficient to initiate and maintain
viral latency within a permissive cellular environment.
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Plasmids
All nucleotide sequence positions are based on the BC-1
KSHV isolate as sequenced by Russo et al. (1996). Plasmids
+271/−279 (LANAp-FL, or pDD83 in previous reports),
pDD104 (LANA expression vector), and pDD163 (vGPCR/
K14p) were described previously (Jeong et al., 2001, 2002,
2004; Damania et al., 2004). Plasmid +271/−279 and
derivatives were from a KS library (Zhong et al., 1996) and
exhibit 100% sequence identity to the KSHV BC-1 sequence.
Plasmid pDD163 was derived from BCBL-1 cells (Komanduri
et al., 1996) and differs from the BC-1 sequence by a T to G
substitution at nt 127,457. Deletion mutants were generated by
first introducing 1-, 2-, or 3-bp substitutions to generate a novel
NcoI, NheI or SacI site (potential sites identified using
PROLOG code (Dittmer, unpublished)) using the GeneTailor™
Site-Directed Mutagenesis System (Invitrogen, Carlsbad, CA)
and the GeneAmp High Fidelity PCR System (Applied
Biosystems, Foster City, CA). Positive substitution mutants
were then subjected to restriction digest to delete a portion of the
promoter sequence followed by subsequent re-ligation of the
reporter construct. For site-directed mutagenesis, the +271/
−279 LANAp-luciferase reporter served as the wild-type full-
length template. To eliminate the possibility that inadvertent
second-site mutations within the luciferase ORF might be
responsible for loss of luciferase activity, the LANAp region of
functionally inactive reporters was subcloned into empty pGL3
basic. The subcloned reporters displayed similar promoter
activity compared to their respective parental reporter, demon-
strating that loss of function was due to the intended mutation/
deletion within the LANA promoter sequence (data not shown).
All mutants were confirmed by DNA sequencing. The
ORF50ΔSTAD expression vector was a kind gift from D.
Lukac (Lukac et al., 1999); the wild-type ORF50 expression
vector was a gift from B. Damania (Damania et al., 2004); the
myc-tagged ORF50 expression vector was a gift from J. Jung;
the ORF50(KK/EE), ORF50(R161A), and ORF50(KK/EE)
(R161A) expression vectors were generous gifts from G. Miller
(Chang et al., 2005).
Tissue culture and transfection
HEK293 cells were obtained from ATCC. SLK cells were
previously described (Herndier et al., 1994). All adherent cells
were cultured in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, penicillin (0.05 μg/ml), and streptomycin (5 U/ml)
(Invitrogen Inc., Carlsbad, CA) at 37 °C under 5% CO2. At day
1, cells were seeded 2–5 × 104 cells/ml/well (12 well plate) to
reach 50% confluency after 24 h. At day 2, 4000 ng of total
DNA was suspended in 150 μl of DMEM (no serum, no
antibiotics) and 10 μl of Superfect (Qiagen Inc., Valencia, CA).
The transfection mixture was incubated for 30 min at room
temperature, the total volume adjusted to 1.5 ml with complete
medium and 0.5 ml of transfection mixture was added pertriplicate well. Cells were incubated overnight at 37 °C under
5% CO2, the medium was exchanged with fresh complete
medium and then harvested 48 h post-transfection.
Immunoblotting
293 cells were first seeded in 10-cm plates then harvested
24 h post-infection in Cell Culture Lysis Reagent (Promega,
Madison, WI); protein concentration of lysates were normalized
by BCA assay (Pierce, Rockford, IL), and the lysate was
subjected to luciferase assay (described below) and separation
by 8% SDS-PAGE, transferred to PVDF membrane then
blocked in 5% non-fat milk in PBST (0.05% Tween-20).
Antibodies were diluted in blocking solution at 1:5000 for anti-
myc-HRP (Invitrogen Inc., Carlsbad, CA), 1:10,000 for
monoclonal anti-beta-actin (clone AC-15) (Sigma, St. Louis,
MS), and 1:15,000 for goat anti-mouse-HRP (Santa Cruz
Biotechnology, Santa Cruz, CA).
Luciferase activity
Firefly luciferase activity was measured 48 h post-transfec-
tion using the Luciferase Assay System (Promega, Madison,
WI) in a BMG Labtech FLUOstar OPTIMA 96-well lumino-
meter with automatic injector according to the manufacturers'
instructions. β-Galactosidase activity was determined using
Galacto-Light Plus Kit (Tropix, Bedford, MA) according to
manufacturers' recommendations. Promoter reporter activities
were normalized to β-galactosidase activity in Figs. 1 and 2.
However, we observed that expression of Rta/ORF50 consis-
tently and significantly affected β-galactosidase expression,
skewing this value as a normalizing factor (data not shown).
Therefore, for experiments where Rta/ORF50 was expressed,
promoter activities were normalized to LANAp-FL (pDDD83)
or pGL3 basic activity. Each series of mutants was transfected
within 3 separate days, each time in triplicate wells. Each well
was lysed and analyzed for luciferase and β-galactosidase
expression independently. All luciferase counts were within the
linear range of the assay, were measured at 0.5-s intervals over
10 s, and final values were derived as the average of interval
readings after the luciferase signal had reached a steady plateau
(2–10 s post-substrate addition).
Real-time quantitative PCR
Quantitative real-time PCR primers were designed using
Primer Express 1.5 (Applied Biosystems, Foster City, CA) and
used as described previously (Dittmer, 2003; Fakhari and
Dittmer, 2002) on an ABI PRIZM 5700 Sequence Detector
(Applied Biosystems, Foster City, CA) using universal cycling
conditions (2 min at 50 °C, 10 min at 95 °C, followed by
40 cycles of 15 s at 95 °C and 1 min at 60 °C). The cycle
threshold values were determined by automated analysis. The
threshold was set to five times the SD of the non-template
control. Dissociation curves were recorded after each run, and
the amplified products were routinely analyzed by 2% agarose
gel electrophoresis (data not shown).
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